Inspire Pharmaceuticals, Inc. Announces Date For Conference Call And Webcast To Discuss Third Quarter 2008 Financial Results

DURHAM, NC - OCTOBER 17, 2008 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report third quarter 2008 financial results on Friday, October 31, 2008 before the market opens. Inspire's President and CEO, Christy L. Shaffer, Ph.D., and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast on Friday, October 31, 2008 at 10:00 a.m. ET.

To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 68985448. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until November 14, 2008. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 68985448.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire is currently developing products for dry eye, cystic fibrosis and glaucoma. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

MORE ON THIS TOPIC